Search results for "Proteins"

showing 10 items of 10069 documents

Role of insulin-like growth factors in autocrine growth of human retinoblastoma Y79 cells.

1996

In this study, we have demonstrated that human retinoblastoma Y79 cells produce insulin-like growth factors (IGFs) type I and type II and release them into the medium. We have also ascertained, by means of competitive studies and cross-linking procedure, that Y79 cells contain the type-I IGF receptor (IGF-IR). Furthermore, surface-bound IGF-I is internalised by the receptor, then degraded to amino acids. Insulin, IGF-I and IGF-II caused down-regulation of IGF-IR; the effect is concentration and time dependant. Scatchard analysis demonstrated that incubation with insulin markedly decreased the binding capacity measured for IGF-I while the apparent Kd value calculated for IGF-I binding was no…

medicine.medical_specialtymedicine.medical_treatmentBiologyBiochemistryBinding CompetitiveReceptor IGF Type 1chemistry.chemical_compoundInsulin-Like Growth Factor IIInternal medicineInsulin receptor substratemedicineHumansInsulinInsulin-Like Growth Factor IAutocrine signallingPhosphotyrosineInsulin-like growth factor 1 receptorInsulinRetinoblastomaTyrosine phosphorylationPhosphoproteinsIRS2Insulin receptorautocrine growthEndocrinologychemistrybiology.proteinInsulin Receptor Substrate ProteinsPlatelet-derived growth factor receptorCell DivisionSignal TransductionEuropean journal of biochemistry
researchProduct

Effect of Soluble Interleukin-6 Receptor on Interleukin-6 Synthesis in Human Skin Fibroblasts

1996

Abstract In this study the ability of soluble interleukin-6 receptor (sIL-6R) to stimulate interleukin-6 (IL-6) synthesis in human fibroblasts is described. It was found that sIL-6R, in combination with endogenous or exogenous IL-6, markedly upregulated IL-6 synthesis. These data suggest that increased IL-6 production after stimulation by either interleukin-1 or tumor necrosis factor-α would result in complex formation with sIL-6R, rapid uptake, and further synthesis of this cytokine. Furthermore, it would explain the decrease in sIL-6R plasma levels observed in patients suffering from sepsis.

medicine.medical_specialtymedicine.medical_treatmentBiophysicsGene ExpressionHuman skinStimulationEndogenyBiochemistryDownregulation and upregulationAntigens CDInternal medicinemedicineHumansInterleukin 6ReceptorMolecular BiologyCells CulturedSkinbiologyInterleukin-6Receptors InterleukinCell BiologyFibroblastsReceptors Interleukin-6Recombinant ProteinsKineticsCytokineEndocrinologybiology.proteinTumor necrosis factor alphaBiochemical and Biophysical Research Communications
researchProduct

Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins

2000

Dendritic cells (DC) are the most potent antigen-presenting cells of the immune system. In this study we investigated the effects of various prostaglandins (PG) on the stimulatory capacity of DC. DC were generated from peripheral progenitor cells in the presence of IL-4 and GM-CSF and stimulated with IL-1, IL-6 and TNF-alpha on day 7. Simultaneously, PG (PGD(2), PGE(1), PGE(2), PGF(2 alpha), PGI(2)) were added at various concentrations (10(-5) to 10(-9) M) on day 7. In all experiments, PGE(2) had the most potent influence on the maturation of the DC, followed by other PG in the order PGE(1) > PGD(2) > PGF(2 alpha) > PGI(2). In addition, the expression of the surface molecules CD40, CD54, CD…

medicine.medical_specialtymedicine.medical_treatmentDermatologyLymphocyte ActivationProinflammatory cytokinechemistry.chemical_compoundInterferon-gammaAntigens CDInternal medicinemedicineHumansCells CulturedMHC class IIForskolinCD40biologyDose-Response Relationship DrugInterleukin-6Prostaglandin D2Tumor Necrosis Factor-alphaColforsinCell DifferentiationGeneral MedicineDendritic cellDendritic CellsMolecular biologyInterleukin-12Coculture TechniquesEndocrinologyCytokinechemistryBucladesinebiology.proteinProstaglandinsCytokinesInterleukin-2lipids (amino acids peptides and proteins)CD80CD8Interleukin-1
researchProduct

Effects of dietary conjugated linoleic acids in the control of adiposity and obesity‐related disorders

2007

The body fat-lowering effect of conjugated linoleic acids (CLA) in experimental animals has attracted much interest because of the potential use of CLA as weight loss agents in humans. The objective of this review was to give an overview of the results from human intervention trials. The review also addresses experimental studies in animal models and in cultured cells. CLA appear to provoke fat mass loss and an increase of fat-free mass in rodents, but the results in humans are inconsistent and much less clear than in rodents. Thus, the results of studies in humans do not support a body fat-lowering effect of CLA. There are indications from animal studies that the trans-10, cis-12 CLA isome…

medicine.medical_specialtymedicine.medical_treatmentLinoleic acidConjugated linoleic acidBiologyIndustrial and Manufacturing Engineeringchemistry.chemical_compoundInsulin resistanceLiver steatosisInternal medicinemedicinechemistry.chemical_classificationintegumentary systemInsulinfood and beveragesGeneral Chemistrymedicine.diseaseObesityEndocrinologyBiochemistrychemistrylipids (amino acids peptides and proteins)Animal studiesFood ScienceBiotechnologyPolyunsaturated fatty acidEuropean Journal of Lipid Science and Technology
researchProduct

Cholesterol as stabilizer of the oxytocin receptor

2002

AbstractThe function of the oxytocin receptor system is strongly dependent on steroids as demonstrated by several physiological studies. One key element of this dependence on steroids may be the interaction of cholesterol and the oxytocin receptor. In this study, we show that cholesterol stabilizes the solubilized human oxytocin receptor against thermal inactivation and proteolytic degradation. In the absence of additional cholesterol, the soluble receptor inactivates within minutes. Maximal stabilization of the oxytocin receptor requires a continuous supply with cholesterol from a cholesterol-rich environment. A structure–activity analysis of various cholesterol analogues and their effect …

medicine.medical_specialtymedicine.medical_treatmentProteolysisGreen Fluorescent ProteinsBiophysicsTransfectionBiochemistrySteroidCell Linechemistry.chemical_compoundInternal medicineEndopeptidasesmedicineHumansDenaturation (biochemistry)ReceptorOxytocin receptormedicine.diagnostic_testCholesterolTemperatureTransfectionCell BiologyHydrogen-Ion ConcentrationOxytocin receptorDenaturationLuminescent ProteinsEndocrinologyCholesterolchemistrySolubilityCell cultureReceptors OxytocinProteolysislipids (amino acids peptides and proteins)hormones hormone substitutes and hormone antagonistsBiochimica et Biophysica Acta (BBA) - Biomembranes
researchProduct

Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up

1987

Ninety-one patients with acute myocardial infarction were assigned to intravenous treatment with streptokinase or rt-PA as part of the randomized trial carried out by the European Study Group for Recombinant Tissue-Type Plasminogen Activator (rt-PA). A patent coronary artery was found in 37 of 45 (82%) patients treated with rt-PA and in 27 of 46 (59%) patients treated with streptokinase 75-90 minutes after start of infusion. Patients were subsequently anticoagulated with heparin or dicoumarol up to a repeat angiography 3 weeks after the infarction. Of the 64 patients with successful reperfusion, 3 died and 3 suffered reocclusion of the vessel. Quantitative analysis of the coronary stenosis …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseInfarctionCoronary DiseaseCoronary AngiographyRandom AllocationReperfusion therapyRecurrenceInternal medicineHumansMedicineStreptokinaseMyocardial infarctionVascular PatencyClinical Trials as Topicmedicine.diagnostic_testbusiness.industryHeparinThrombolysisMiddle Agedmedicine.diseaseRecombinant Proteinsmedicine.anatomical_structureTissue Plasminogen ActivatorAngiographyCardiologyCineangiographyRadiographic Image Interpretation Computer-AssistedCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugArteryEuropean Heart Journal
researchProduct

Ultrasound-induced blood clot dissolution without a thrombolytic drug is more effective with lower frequencies.

2004

<i>Background and Purpose:</i> Therapeutic ultrasound as stand-alone therapy or in combination with rt-PA has proven to be an effective measure for recanalisation of acute vessel occlusion in different in vitro and in vivo studies. Uncertainty still exists concerning the optimal frequency and intensity with regard to the thrombolytic efficacy of ultrasound. The purpose of this study was a direct comparison of different ultrasound frequencies, when otherwise using identical measurement settings and parameters. <i>Methods:</i> Ultrasound-induced dissolution of fresh human blood clots was studied in a flow system using low-frequency continuous wave ultrasound of 20, 40 …

medicine.medical_specialtymedicine.medical_treatmentVessel occlusionThrombolytic drugInternal medicinemedicineHumansThrombolytic TherapyUltrasonicsStrokeBlood CoagulationUltrasonographyTherapeutic ultrasoundbusiness.industryUltrasoundAnticoagulantsThrombolysisFrequency dependencemedicine.diseaseRecombinant ProteinsSurgeryBloodNeurologyCalibrationCardiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCerebrovascular diseases (Basel, Switzerland)
researchProduct

Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

2017

Abstract Introduction and objectives The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1. Methods Multicenter, open-label, parallel clinical trial, in which patients with AHF and serum creatinine ≥ 1.4 mg/dL on admission will be randomized to: a) standard diuretic str…

medicine.medical_specialtymedicine.medical_treatmentWater-Electrolyte ImbalanceRenal functionCardiorenal syndrome030204 cardiovascular system & hematologyPatient Care Planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFurosemideInternal medicineHumansMedicine030212 general & internal medicineDiureticsIntensive care medicineHeart FailureCreatinineCardio-Renal Syndromebusiness.industryClinical study designChlorthalidoneMembrane ProteinsGeneral Medicinemedicine.diseasePathophysiologyAcetazolamideClinical trialchemistryCA-125 AntigenCreatinineHeart failureAcute DiseaseCardiologyDiureticbusinessRevista Española de Cardiología (English Edition)
researchProduct

Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol suppl…

2007

Objective— Phospholipid transfer protein (PLTP) is a multifunctional, extracellular lipid transport protein that plays a major role in lipoprotein metabolism and atherosclerosis. Recent in vivo studies suggested that unlike systemic PLTP, macrophage-derived PLTP would be antiatherogenic. The present study aimed at characterizing the atheroprotective properties of macrophage-derived PLTP. Methods and Results— Peritoneal macrophages were isolated from PLTP-deficient and wild-type mice and their biochemical characteristics were compared. It is shown that macrophages isolated from PLTP-deficient mice have increased basal cholesterol content and accumulate more cholesterol in the presence of LD…

medicine.medical_specialtymedicine.medical_treatmentalpha-TocopherolOxidative phosphorylationBiologychemistry.chemical_compoundMiceIn vivoPhospholipid transfer proteinInternal medicineMalondialdehydeExtracellularmedicineAnimalsTocopherolPhospholipid Transfer ProteinsMice KnockoutCholesterolVitamin EVitaminsLipoproteins LDLEndocrinologyCholesterolchemistryBiochemistryDietary SupplementsMacrophages Peritoneallipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinealpha-TocopherolArteriosclerosis, thrombosis, and vascular biology
researchProduct

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

2022

Background Circulating dysfunctional factor IX (FIX) might modulate distribution of infused FIX in hemophilia B (HB) patients. Recurrent substitutions at FIX activation sites (R191-R226, >300 patients) are associated with variable FIX activity and antigen (FIXag) levels. Objectives To investigate the (1) expression of a complete panel of missense mutations at FIX activation sites and (2) contribution of F9 genotypes on the FIX pharmacokinetics (PK). Methods We checked FIX activity and antigen and activity assays in plasma and after recombinant expression of FIX variants and performed an analysis of infused FIX PK parameters in patients (n = 30), mostly enrolled in the F9 Genotype and PK HB …

medicine.medical_specialtypharmacogenetics.Mutation MissenseSocio-culturaleAlpha (ethology)aemophilia Brecombinant proteinsHemophilia Blaw.inventionFactor IXAntigenlawInternal medicineGenotypemedicineMissense mutationHumansHaemophilia BpharmacokineticBeta (finance)Factor IXpharmacogeneticsChemistryHematologymedicine.diseaseEndocrinologyPhenotypefactor IX activation; hemophilia B; pharmacogenetics; pharmacokinetics; recombinant proteinsRecombinant DNAFemalefactor IX activationBlood Coagulation Testspharmacokineticsrecombinant proteinmedicine.drugJournal of thrombosis and haemostasis : JTH
researchProduct